Hellen McKinnon Edwards
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hellen McKinnon Edwards has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Landorph
Novo Nordisk A/S, 2860 Søborg, Denmark
2 shared publications - Cameron Wellard
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
2 shared publications - Camila Caram-Deelder
Department of Clinical Epidemiology Leiden University Medical Center Leiden the Netherlands
2 shared publications - Camilla Birkegård
Novo Nordisk A/S, 2860 Søborg, Denmark
2 shared publications - Daniel Surbek
Department of Obstetrics and Gynecology, University Hospital Bern, University of Bern, Bern, Switzerland
2 shared publications - Derek Van Duuren
Leiden University Medical Center, 2333 Leiden, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 2 June 2024
- Published by Danish Journal of Obstetrics and Gynaecology in Danish Journal of Obstetrics and Gynaecology
- Vol. 3 (1) , 81-89
DSOG Guideline Bulletin: Retained Products of Conception in Postpartum Women
The aim of this guideline was to update an existing guideline from 2014. Retained products of conception (RPOC) is a recognized cause of secondary postpartum hemorrhage (PPH), affecting 1-6% of postpartum women. Despite its clinical significance, evidence on the diagnosis and management of RPOC remains limited. This guideline provides recommendations for both hemodynamically stable and unstable patients. Seven research questions were formulated to evaluate diagnostic methods of RPOC and compare different treatment modalities. The level of evidence was graded according to the Oxford Centre for Evidence-based Medicine Levels of Evidence depending on the study quality. According to the literature diagnosis of RPOC remains challenging, as RPOC can mimic normal postpartum uterine changes on ultrasound. Ultrasound, particularly with Doppler flow, plays a valuable role in diagnosis of RPOC, and findings such as a midline echo ≥10 mm or an intracavitary hyperechogenic mass should be correlated with clinical symptoms to guide management. Management options include watchful waiting and surgical intervention. Medical management has shown limited success, often necessitating secondary surgical treatment. Watchful waiting may be considered in hemodynamically stable patients regardless of ultrasonographic findings, although comparative data with active treatment is inconclusive. Surgical treatments include dilation and curettage (D&C) or hysteroscopic resection. Though widely used, D&C is a blind procedure with risks such as uterine perforation and intrauterine adhesions, potentially affecting future fertility. Hysteroscopy, offering direct visualization and targeted removal, minimizes endometrial damage and adhesions and is increasingly preferred where expertise and resources are available. Hemodynamically unstable patients with ongoing severe bleeding may undergo D&C, preferably guided by ultrasound. Hysteroscopy within the first postpartum weeks, especially in the presence of ongoing heavy bleeding, can be technically difficult to conduct, but is the preferred choice when possible. The level of evidence across studies ranged from 2b to 4, emphasizing the need for further research in this field.
- 2 June 2024
- Published by Danish Journal of Obstetrics and Gynaecology in Danish Journal of Obstetrics and Gynaecology
- Vol. 3 (1) , 81-89
Open AccessDSOG Guideline Bulletin: Retained Products of Conception in Postpartum Women
The aim of this guideline was to update an existing guideline from 2014. Retained products of conception (RPOC) is a recognized cause of secondary postpartum hemorrhage (PPH), affecting 1-6% of postpartum women. Despite its clinical significance, evidence on the diagnosis and management of RPOC remains limited. This guideline provides recommendations for both hemodynamically stable and unstable patients. Seven research questions were formulated to evaluate diagnostic methods of RPOC and compare different treatment modalities. The level of evidence was graded according to the Oxford Centre for Evidence-based Medicine Levels of Evidence depending on the study quality. According to the literature diagnosis of RPOC remains challenging, as RPOC can mimic normal postpartum uterine changes on ultrasound. Ultrasound, particularly with Doppler flow, plays a valuable role in diagnosis of RPOC, and findings such as a midline echo ≥10 mm or an intracavitary hyperechogenic mass should be correlated with clinical symptoms to guide management. Management options include watchful waiting and surgical intervention. Medical management has shown limited success, often necessitating secondary surgical treatment. Watchful waiting may be considered in hemodynamically stable patients regardless of ultrasonographic findings, although comparative data with active treatment is inconclusive. Surgical treatments include dilation and curettage (D&C) or hysteroscopic resection. Though widely used, D&C is a blind procedure with risks such as uterine perforation and intrauterine adhesions, potentially affecting future fertility. Hysteroscopy, offering direct visualization and targeted removal, minimizes endometrial damage and adhesions and is increasingly preferred where expertise and resources are available. Hemodynamically unstable patients with ongoing severe bleeding may undergo D&C, preferably guided by ultrasound. Hysteroscopy within the first postpartum weeks, especially in the presence of ongoing heavy bleeding, can be technically difficult to conduct, but is the preferred choice when possible. The level of evidence across studies ranged from 2b to 4, emphasizing the need for further research in this field.
- Open Access
- 1 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2656
Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage
Background: Despite a range of available treatments, it is still sometimes challenging to treat patients with severe post-partum hemorrhage (sPPH). Objective: This study evaluated the efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 (NCT04723979), OS-2, OS-3, and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligations, arterial embolization, or hysterectomy) and safety (incidence of thromboembolic events (TE) and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa-exposed women only. Results: A total of 446 women exposed to rFVIIa and 1717 non-exposed controls were included. In the RCT, fewer rFVIIa-exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio: 0.11; 95% confidence interval: 0.03–0.35). In OS-1, more rFVIIa-exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio: 2.46; 95% confidence interval: 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa-exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio: 0.33; 95% confidence interval: 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa-exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa on the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
- 1 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2656
Open AccessEfficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage
Background: Despite a range of available treatments, it is still sometimes challenging to treat patients with severe post-partum hemorrhage (sPPH). Objective: This study evaluated the efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 (NCT04723979), OS-2, OS-3, and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligations, arterial embolization, or hysterectomy) and safety (incidence of thromboembolic events (TE) and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa-exposed women only. Results: A total of 446 women exposed to rFVIIa and 1717 non-exposed controls were included. In the RCT, fewer rFVIIa-exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio: 0.11; 95% confidence interval: 0.03–0.35). In OS-1, more rFVIIa-exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio: 2.46; 95% confidence interval: 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa-exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio: 0.33; 95% confidence interval: 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa-exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa on the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
- Open Access
- 4 March 2024
- Published by MDPI AG in Preprints.org
Efficacy and Safety Analysis of Recombinant Factor VIIa in Severe Post-partum Hemorrhage
Background: Despite a range of available treatments, there is a remaining unmet need for patients with severe post-partum hemorrhage (sPPH). Objective: This manuscript evaluated efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 [NCT04723979], OS-2, OS-3 and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligation, arterial embolization or hysterectomy) and safety (incidence of thromboembolic events [TE] and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa exposed women only. Results: A total of 446 women exposed to rFVIIa and 1,717 non-exposed controls were included. In the RCT, fewer rFVIIa exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio 0.11, 95% confidence interval 0.03–0.35). In OS-1, more rFVIIa exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio 2.46, 95% confidence interval 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio 0.33, 95% confidence interval 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa in the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
- 4 March 2024
- Published by MDPI AG in Preprints.org
Open AccessEfficacy and Safety Analysis of Recombinant Factor VIIa in Severe Post-partum Hemorrhage
Background: Despite a range of available treatments, there is a remaining unmet need for patients with severe post-partum hemorrhage (sPPH). Objective: This manuscript evaluated efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 [NCT04723979], OS-2, OS-3 and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligation, arterial embolization or hysterectomy) and safety (incidence of thromboembolic events [TE] and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa exposed women only. Results: A total of 446 women exposed to rFVIIa and 1,717 non-exposed controls were included. In the RCT, fewer rFVIIa exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio 0.11, 95% confidence interval 0.03–0.35). In OS-1, more rFVIIa exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio 2.46, 95% confidence interval 1.06–5.99). In OS-2, 17% (3/18) of rFVIIa exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio 0.33, 95% confidence interval 0.03–1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa in the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
- 7 February 2019
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 299 (3) , 733-740
The increasing role of a retained placenta in postpartum blood loss: a cohort study
To describe the association between quantity of blood loss, duration of the third stage of labour, retained placenta and other risk factors, and to describe the role of a retained placenta depending on the cutoff used to define postpartum haemorrhage.
- 7 February 2019
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 299 (3) , 733-740
The increasing role of a retained placenta in postpartum blood loss: a cohort study
To describe the association between quantity of blood loss, duration of the third stage of labour, retained placenta and other risk factors, and to describe the role of a retained placenta depending on the cutoff used to define postpartum haemorrhage.
- 1 March 2018
- Vol. 65 (3)
Aetiology and treatment of severe postpartum haemorrhage
This thesis is comprised of three studies focusing on severe postpartum haemorrhage (PPH). PPH is a major cause of maternal morbidity and mortality worldwide. Risk factors include retained placenta, prolonged duration of the third stage of labour, previous caesarean section, and operative vaginal delivery. Occurrence and development of PPH are, however, unpredictable and can sometimes give rise to massive haemorrhage or even hysterectomy and maternal death. Severe haemorrhage can lead to coagulopathy causing further haemorrhage and requiring substitution with blood transfusions. The aim of this thesis was to investigate causes of severe PPH and investigate methods of early prevention. The first study was a randomised controlled double-blinded trial investigating the effect of treatment with pre-emptive fibrinogen on women with severe PPH. The primary outcome was the need for red blood cell transfusion at 6 weeks postpartum. A total of 249 women were randomised to either 2 grams of fibrinogen or placebo. The mean concentration of fibrinogen increased significantly in the intervention group compared to the placebo group (0.40 g/L, confidence interval: 0.15-0.65), but there was no difference in the need for postpartum blood transfusions (relative risk 0.95, confidence interval: 0.15-1.54). No thromboembolic complications were detected. The second study was a population-based observational study including 245 women receiving >= 10 RBCs due to PPH. The cohort was identified by combining data from The Danish Transfusion Database with The Danish Medical Birth Registry, with further data extraction and validation through review of patient charts. The main causes of massive postpartum transfusion were atony (38%) and abnormal invasive placenta (25%). Two of the women in the cohort died, an additional six had a cardiac arrest, and a total of 128 women (52%) required a hysterectomy. Hysterectomy was associated with increased blood loss, increased number of blood transfusions, a higher fresh frozen plasma to red blood cell ratio (p=0.010), and an increased number of red blood cells before first platelet transfusion (p=0.023). Hysterectomy led to haemostasis in only 70% of cases. The third study was a register-based cohort study, including 43,357 vaginal deliveries from two large Danish maternity units. Different cut-offs were used to define PPH. There was a difference in distribution of causes depending on the cut-off used, with atony playing a decreasing role and a retained placenta an increasing role the higher the cut-off used. In a multivariate linear regression model retained placenta was identified as a strong predictor of quantity of blood loss. The duration of the third stage of labour was a very weak predictor after adjusting for the influence of a retained placenta. In conclusion, an improved diagnosis of the causes of PPH especially retained placenta, together with an early recognition and treatment of coagulopathy, seem to be important in reducing severe PPH in an aim to minimize associated maternal morbidity.
- 1 March 2018
- Vol. 65 (3)
Aetiology and treatment of severe postpartum haemorrhage
This thesis is comprised of three studies focusing on severe postpartum haemorrhage (PPH). PPH is a major cause of maternal morbidity and mortality worldwide. Risk factors include retained placenta, prolonged duration of the third stage of labour, previous caesarean section, and operative vaginal delivery. Occurrence and development of PPH are, however, unpredictable and can sometimes give rise to massive haemorrhage or even hysterectomy and maternal death. Severe haemorrhage can lead to coagulopathy causing further haemorrhage and requiring substitution with blood transfusions. The aim of this thesis was to investigate causes of severe PPH and investigate methods of early prevention. The first study was a randomised controlled double-blinded trial investigating the effect of treatment with pre-emptive fibrinogen on women with severe PPH. The primary outcome was the need for red blood cell transfusion at 6 weeks postpartum. A total of 249 women were randomised to either 2 grams of fibrinogen or placebo. The mean concentration of fibrinogen increased significantly in the intervention group compared to the placebo group (0.40 g/L, confidence interval: 0.15-0.65), but there was no difference in the need for postpartum blood transfusions (relative risk 0.95, confidence interval: 0.15-1.54). No thromboembolic complications were detected. The second study was a population-based observational study including 245 women receiving >= 10 RBCs due to PPH. The cohort was identified by combining data from The Danish Transfusion Database with The Danish Medical Birth Registry, with further data extraction and validation through review of patient charts. The main causes of massive postpartum transfusion were atony (38%) and abnormal invasive placenta (25%). Two of the women in the cohort died, an additional six had a cardiac arrest, and a total of 128 women (52%) required a hysterectomy. Hysterectomy was associated with increased blood loss, increased number of blood transfusions, a higher fresh frozen plasma to red blood cell ratio (p=0.010), and an increased number of red blood cells before first platelet transfusion (p=0.023). Hysterectomy led to haemostasis in only 70% of cases. The third study was a register-based cohort study, including 43,357 vaginal deliveries from two large Danish maternity units. Different cut-offs were used to define PPH. There was a difference in distribution of causes depending on the cut-off used, with atony playing a decreasing role and a retained placenta an increasing role the higher the cut-off used. In a multivariate linear regression model retained placenta was identified as a strong predictor of quantity of blood loss. The duration of the third stage of labour was a very weak predictor after adjusting for the influence of a retained placenta. In conclusion, an improved diagnosis of the causes of PPH especially retained placenta, together with an early recognition and treatment of coagulopathy, seem to be important in reducing severe PPH in an aim to minimize associated maternal morbidity.